Cancer antigen 125 levels in inflammatory bowel diseases

Journal of Clinical Laboratory Analysis

Volumn 23, Issue 4, 2009, Pages 244-248

  Ataseven, Hilmi ^a   Öztürk, Zeynel Abidin ^b   Arhan, Mehmet ^c   Yüksel, Osman ^d,e   Köklü, Seyfettin ^b   Ibiş, Mehmet ^c   Başar, Ömer ^d   Yilmaz, Fatma Meriç ^b   Yüksel, Ilhami ^d  

^a Department of Gastroenterology   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^d DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e NONE   (Turkey)

Author keywords

Cancer antigen 125; Crohn's disease; Ulcerative colitis

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ULCERATIVE COLITIS;

ADULT; CA-125 ANTIGEN; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; TUMOR MARKERS, BIOLOGICAL;

EID: 68049113243     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20323     Document Type: Article

References (31)

1. Kucharzik T, Maaser C, Lügering A, et al. Recent understanding of IBD pathogenesis: Implications for future therapies. Inflamm Bowel Dis 2006;12:1068-1083. (Pubitemid 44665477)
2. Goyette P, Labbé C, Trinh TT, Xavier RJ, Rioux JD. Molecular pathogenesis of inflammatory bowel disease: Genotypes, phenotypes and personalized medicine. Ann Med 2007;39:177-199. (Pubitemid 46676480)
3. Bruining DH, Loftus EV. Current and future diagnostic approaches: From serologies to imaging. Curr Gastroenterol Rep 2007;9:489-496. (Pubitemid 351795707)
4. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: Monitoring disease activity. Aliment Pharmacol Ther 2003;17:11-17. (Pubitemid 36831453)
5. Bitton A, Peppercorn M, Antonioli D, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20. (Pubitemid 32061864)
6. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006;55:426-431.
7. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712. (Pubitemid 41271173)
8. Sandborn WJ, Loftus EV, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative and Crohn's disease. Inflamm Bowel Dis 2001;7:192-201.
9. Dorigo O, Berek JS. CA125: Megadaltons of novel opportunities. Gynecol Oncol 2007;104:505-507.
10. Høgdall E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008;20:4-8.
11. Miralles C, Orea M, Espana P, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150-154. (Pubitemid 40485935)
12. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-1048.
13. Best WR, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989;298:82-86. (Pubitemid 19032930)
15. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-734. (Pubitemid 32240723)
16. Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:449-454. (Pubitemid 32184933)
17. Kane SV, Sandborn WJ, Zholudev A, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-1314. (Pubitemid 36741528)
18. Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 1998;93:1300-1305. (Pubitemid 29076931)
19. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastrotenterol 2004;39:1017-1020. (Pubitemid 39388470)
20. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008;51:1283-1291.
21. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP and clinical indices. Am J Gastroenterol 2008;103:162-169.
22. Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 2007;67:810-820. (Pubitemid 350158774)
23. Bast Jr RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.
24. Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA 125 production by the peritoneum: In vitro and in vivo studies. Hum Reprod 2000;15:1261-1265.
25. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994;47:263-265. (Pubitemid 24120692)
26. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005;7:199-203.
27. Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: Relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 2008;10:556-559.
28. Bamias G, Nyce MR, De La Rue SA, Cominelli F. American College of Physicians; American Physiological Society. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005;143:895-904.
29. Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1419-1423. (Pubitemid 350206856)
30. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res 2007;149:173-186. (Pubitemid 46442010)
31. Guimbaud R, Bertrand V, Chauvelot-Moachon L, et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998;93:2397-2404. (Pubitemid 29018545)